NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/28/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization219.39 mln
Float136 mln
Earnings Date11/09/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
3.78
Highly suspicious
1-Year Forecast
7.75
Transformational upside
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.65
Moderate leverage
ROE
-162
Deeply negative
Business Description
Coherus Oncology is a US-based biopharmaceutical company focused on developing and selling cancer treatments, including approved therapies and drugs still in clinical testing. Its portfolio includes a biosimilar supporting immune recovery during chemotherapy, an approved checkpoint inhibitor for certain head and neck cancers, and several experimental antibody-based therapies targeting the tumor environment. The company works alongside a number of partners, including Junshi Biosciences, Novartis, and GlaxoSmithKline, through licensing and co-development agreements. Founded in 2010 and headquartered in Redwood City, California, the company rebranded under its current name in May 2025.
